{"filing":{"accession_number":"0001787306-26-000049","cik":"0001787306","ticker":"ARQT","company_name":"Arcutis Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-07-31","primary_document":"arqt-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/arqt-20260731.htm"},"events":[{"id":25246,"run_id":22909,"accession_number":"0001787306-26-000049","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Arcutis reported Q2 2026 financial results with product revenues of $129.9 million (up 59% year-over-year) and net income of $15.0 million ($0.11 per share). The company raised its full-year 2026 guidance to $525–$540 million.","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26019,"accession_number":"0001787306-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including product revenues of $129.9 million (+59% YoY), net income of $15.0 million ($0.11 per share), and raised full-year 2026 guidance to $525–$540 million. The filing includes condensed consolidated balance sheets and statements of operations, which are hallmarks of an earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:22:24.397800+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25247,"run_id":22909,"accession_number":"0001787306-26-000049","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Robert Lisicki was appointed as interim executive vice president and interim chief commercial officer effective August 21, 2026, following L. Todd Edwards' resignation. Lisicki's compensation includes a base salary of $555,000, 50% target bonus, 145,000 option grant, and 55,000 RSUs, with severance arrangements.","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26020,"accession_number":"0001787306-26-000049","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Robert Lisicki as interim executive vice president and interim chief commercial officer effective August 21, 2026, following L. Todd Edwards' resignation. While the section includes both a departure (Edwards) and an appointment (Lisicki), the principal disclosed action centers on Lisicki's appointment with detailed compensation terms (base salary $555,000, 50% target bonus, 145,000 option grant, 55,000 RSUs) and severance arrangements. The appointment of an experienced executive to a critical commercial leadership role is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:22:24.397800+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26019,"accession_number":"0001787306-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including product revenues of $129.9 million (+59% YoY), net income of $15.0 million ($0.11 per share), and raised full-year 2026 guidance to $525–$540 million. The filing includes condensed consolidated balance sheets and statements of operations, which are hallmarks of an earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:22:24.397800+00:00","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-08-05"},{"id":26020,"accession_number":"0001787306-26-000049","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Robert Lisicki as interim executive vice president and interim chief commercial officer effective August 21, 2026, following L. Todd Edwards' resignation. While the section includes both a departure (Edwards) and an appointment (Lisicki), the principal disclosed action centers on Lisicki's appointment with detailed compensation terms (base salary $555,000, 50% target bonus, 145,000 option grant, 55,000 RSUs) and severance arrangements. The appointment of an experienced executive to a critical commercial leadership role is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:22:24.397800+00:00","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-08-05"}]}